Links between donor macrosteatosis, interleukin-33 and complement after liver transplantation

Table 4 Recipient demographics based on donor macrosteatosis

Characteristic		< 30%	≥ 30%	P value
Donor macrosteatosis
Recipient Cohort		94	5
Age/yr	Median (range)	59 (21-72)	39 (18-69)	0.01b
Gender/male	n (%)	57 (61)	4 (80)	0.36
MELD at transplant	Median (range)	21 (6-38)	14 (8-34)	0.90
Etiology
EtOH	n (%)	24 (26)	1 (20)
NASH	n (%)	20 (21)	3 (60)
HCC	n (%)	18 (19)
HCV	n (%)	9 (10)
Other	n (%)	23 (24)	1 (20)
Peak AST (Day 1-7)/(IU/L)	Median (range)	617 (144-13645)	5195 (321-9829)	0.001c
Peak ALT (Day 1-7)/(IU/L)	Median (range)	494 (87-4253)	1327 (398-5002)	0.004b
INR (Day 7)	Median (range)	1.1 (0.9-2.5)	1.1 (1.0-1.5)	0.60
Bilirubin (Day 7)/(mg/dL)	Median (range)	1.9 (0.5-11)	4.6 (1.3-16.8)	0.03a
No EAD	n (%)	77 (82)	2 (40)
EAD	n (%)	17 (18)	3 (60)	0.04a

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

MELD: Model for end-stage liver disease; EtOH: Alcoholic hepatitis; NASH: Nonalcoholic steatohepatitis; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; AST: Aspartate transaminase; ALT: Alanine aminotransferase; INR: International normalized ratio; EAD: Early allograft dysfunction.